BPG is committed to discovery and dissemination of knowledge
Observational Study
©The Author(s) 2025.
World J Clin Oncol. Dec 24, 2025; 16(12): 111601
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.111601
Table 2 Dosimetric outcomes of target volume and organs at risks
ROIs
Dosimetric metrics
Adapted plan + iCBCT1
Adapted plan + iCBCT2
Scheduled plan + iCBCT1
Scheduled plan + iCBCT2
P1 value
P2 value
CTV-NV100% (%)99.94 ± 0.0999.08 ± 8.8897.02 ± 6.4796.40 ± 10.720.450.34
CTV-ND99% (%)100.87 ± 0.20100.04 ± 8.96100.03 ± 1.4199.36 ± 9.070.990.16
CTV-VV100% (%)99.97 ± 0.0598.66 ± 9.0296.11 ± 3.7196.41 ± 9.80< 0.050.58
CTV-VD99% (%)100.84 ± 0.1999.07 ± 10.5792.97 ± 9.0095.65 ± 11.15< 0.05< 0.05
BladderV40Gy (%)24.62 ± 4.5426.22 ± 5.3226.16 ± 5.8027.35 ± 6.00< 0.05< 0.05
V30Gy (%)38.49 ± 5.9340.25 ± 6.2840.62 ± 6.9641.80 ± 6.83< 0.05< 0.05
V20Gy (%)59.72 ± 7.0561.54 ± 7.0163.13 ± 8.9964.19 ± 8.37< 0.050.09
V10Gy (%)92.40 ± 3.7892.91 ± 3.4094.10 ± 3.9194.19 ± 3.55< 0.050.75
Dmean (Gy)26.77 ± 1.9527.38 ± 2.0627.71 ± 2.5528.10 ± 2.48< 0.05< 0.05
RectumV40Gy (%)38.18 ± 9.2637.36 ± 11.0139.39 ± 14.4637.74 ± 13.820.470.11
V30Gy (%)56.53 ± 10.4256.49 ± 11.3659.77 ± 14.1558.79 ± 13.530.060.33
V20Gy (%)74.13 ± 9.6474.70 ± 9.7979.11 ± 10.5178.84 ± 10.04< 0.050.71
V10Gy (%)94.27 ± 4.6194.42 ± 4.6795.54 ± 4.0195.71 ± 3.75< 0.050.55
Dmean (Gy)31.67 ± 3.3931.61 ± 3.6032.82 ± 4.2932.48 ± 4.000.060.26
BowelV40Gy (%)12.48 ± 6.399.92 ± 5.4412.93 ± 6.7310.24 ± 5.83< 0.05< 0.05
V30Gy (%)23.83 ± 10.9121.11 ± 10.3825.38 ± 11.9922.11 ± 11.36< 0.05< 0.05
V20Gy (%)41.30 ± 17.0239.45 ± 17.0447.04 ± 19.7844.79 ± 19.83< 0.050.11
V10Gy (%)60.24 ± 24.2559.60 ± 24.7469.08 ± 27.9268.75 ± 28.370.360.88
Dmean (Gy)18.05 ± 7.3317.23 ± 7.1719.83 ± 8.1218.93 ± 7.910.070.12


Write to the Help Desk